Amgen’s Purchase of Cancer Drugmaker Biovex May Mean More Deals

Amgen Inc.’s purchase of Biovex, the maker of an experimental cancer vaccine, for as much as $1 billion may signal more deals that aim to push the biotechnology company deeper into tumor treatment.
Bloomberg Businessweek